Literature DB >> 2557218

New in vivo model to assess venous endothelial cell functions. Effect of defibrotide.

T Di Perri1, F Laghi Pasini, C Frigerio, P L Capecchi, G L Messa, M Franchi, F Landini, A Burresi, A Ghezzi, L Ceccatelli.   

Abstract

In the past few years there has been increasing interest in the role of the vascular endothelium as an active modulator of biological responses. Endothelial cells exert antithrombotic activity by the release of prostacyclin [23] and adenine nucleotides [16], the availability on the cell surface of heparin-like substances [3], and thrombomodulin-mediated activation of protein C [8]. In addition, endothelium is involved in the regulation of fibrinolysis by releasing soluble factors, such as tissue plasminogen activator (tPA; [10]) and plasminogen activator inhibitor (PAI; [22, 11]), as well as in the control of vascular responsiveness by the production of smooth muscle relaxing and contracting factors. Endothelial cells have also been shown to synthesize and to express procoagulant activities [18]. Many data on endothelial cell functions has been obtained from two experimental models, namely endothelial cell cultures and perfused segments of animal and human vessels. Both are subject to methodological criticism since they only represent in part in vivo conditions, and the necessary experimental manipulations and laboratory procedures greatly modify the naturally occurring cellular functions. In order to overcome such difficulties as far as possible, a new in vivo model has been employed to provide easily assessable and reliable data on the properties of endothelial cells in man. A venous segment was isolated functionally by cannulating a dorsal vein in the hand and a cubital vein in the same arm. Changes observed ex vivo in blood from the cubital vein following infusion into the hand vein of an active drug, can mainly be attributed to its local effect on the venous wall. At the same time, a cubital vein in the other arm was cannulated in order to provide information to distinguish systemic from regional effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2557218     DOI: 10.1007/BF00558499

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.

Authors:  G Avellone; V Mandalà; A Pinto; A Martino; A Strano
Journal:  Haemostasis       Date:  1986

2.  Effects of defibrotide on peripheral obliterative vascular diseases.

Authors:  O N Ulutin; N Ilhan-Berkel; H Tunali; M Ozer; S Balkuv-Ulutin; C Onsel; I Urgancioğlu
Journal:  Haemostasis       Date:  1986

3.  Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

Authors:  J A van Mourik; D A Lawrence; D J Loskutoff
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

4.  Pharmacokinetics of Defibrotide and of its profibrinolytic activity in the rabbit.

Authors:  R Pescador; M Mantovani; G Prino; M Madonna
Journal:  Thromb Res       Date:  1983-04-01       Impact factor: 3.944

5.  Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

Authors:  C T Esmon; W G Owen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

6.  Antithrombotic activity of a polydeoxyribonucleotidic substance extracted from mammalian organs: a possible link with prostacyclin.

Authors:  R Niada; M Mantovani; G Prino; R Pescador; F Berti; C Omini; G C Folco
Journal:  Thromb Res       Date:  1981-08-01       Impact factor: 3.944

7.  Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides.

Authors:  J D Pearson; J L Gordon
Journal:  Nature       Date:  1979-10-04       Impact factor: 49.962

8.  Effect of a new antithrombotic agent (defibrotide) in acute renal failure due to thrombotic microangiopathy.

Authors:  V Bonomini; G M Frascà; C Raimondi; G Liviano D'arcangelo; A Vangelista
Journal:  Nephron       Date:  1985       Impact factor: 2.847

9.  Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187.

Authors:  B B Weksler; C W Ley; E A Jaffe
Journal:  J Clin Invest       Date:  1978-11       Impact factor: 14.808

10.  Effectiveness of defibrotide for prophylaxis of deep venous thrombosis in gynecological surgery: a double-blind, placebo-controlled clinical trial.

Authors:  N Ciavarella; C Ettorre; M Schiavoni; S Schonauer; E Cicinelli; G Cagnazzo
Journal:  Haemostasis       Date:  1986
View more
  2 in total

Review 1.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.

Authors:  K J Palmer; K L Goa
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

2.  Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.

Authors:  M Tubaro; G Mattioli; F Matta; C Cappello; E Natale; R Ricci; P Gerardi; F Milazzotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.